Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its experimental glaucoma treatment, BL1107, failed to meet its primary goal in a mid …
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
view original post